TFA
TLX

Transamerica Financial Advisors’s Telix Pharmaceuticals TLX Stock Holding History

Transamerica Financial Advisors’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$680 Buy
59
+31
+111% +$316 ﹤0.01% 1604
2026
Q1 		$267 Buy
28
+3
+12% +$23 ﹤0.01% 1581
2025
Q4 		$187 Hold
25
– – ﹤0.01% 1547
2025
Q3 		$239 Buy
+25
New +$306 ﹤0.01% 1421

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Transamerica Financial Advisors's TLX Position: Q2 2026 in Review

Transamerica Financial Advisors increased its Telix Pharmaceuticals (TLX) stake by 111% in Q2 2026, buying an estimated $316 and bringing the position to 59 shares worth $680. The position accounts for ﹤0.01% of the portfolio, ranked #1604.

Transamerica Financial Advisors first reported a position in TLX in Q3 2025 and has held it in 4 quarters since. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Transamerica Financial Advisors held 59 shares of Telix Pharmaceuticals worth $680 as of Q2 2026.
  • Transamerica Financial Advisors bought 31 Telix Pharmaceuticals shares in Q2 2026, an estimated $316.
  • Telix Pharmaceuticals made up ﹤0.01% of Transamerica Financial Advisors's portfolio in Q2 2026, its #1604 holding.
  • Transamerica Financial Advisors first reported a position in Telix Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.